ClinicalTrials.gg
CompletedNCT07412080Updated Feb 17, 2026

EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia

A Phase 1 interventional study of EDP167 and Placebo in Healthy Adult Male and Female Volunteers and Mild Dyslipidemia, sponsored by Eddingpharm (Zhuhai) Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Eddingpharm (Zhuhai) Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jul 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Dyslipidemias with a site in China — 21 open to participants now, 31 under way, 10 of them phase 3. Dyslipidemias · China.

Enrollment
50th of 56
40 · median 213
Started
2025
with 9 others
Phase 1
6 of 73
1 open now
Registered
64th of 73
by date
Lead sponsor
3 of 73
Eddingpharm (Zhuhai) Co., Ltd.

Among the 73 studies in Dyslipidemias with a site in China, this one is the 50th largest by enrollment of the 56 interventional ones that give a count, is one of 10 that started in 2025, is one of 6 in phase 1, and was the 64th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

21 of the 73 studies in Dyslipidemias with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Dyslipidemias with a site in China, or all of them as a file.
02

Study summary

EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions. This is the first in human study of EDP167 in health volunteers and subjects with mild dyslipidemia to evaluate the safety and PK/PD profiles of EDP167.

Read the detailed description

Angiopoietin-like 3 protein (ANGPTL3) is a key regulator of lipid metabolism. Clinical studies have shown that inhibition of ANGPTL3 could exert lipid-lowering effects in patients with dyslipidemia. EDP167 is a novel GalNAc-conjugated siRNA therapeutic that selectively silences hepatic ANGPTL3 mRNA expression, offering a promising strategy for lipid lowering. In this trial, subjects will be sequentially enrolled into five cohorts (35, 100, 200, 300 or 400 mg), each consists of six subjects receiving EDP167 and two receiving matching placebos. The follow-up will last for 85 days to evaluate the PK profile and PD effects (ANGPTL3, LDL-C, TG, and other lipid parameters) following a single subcutaneous injection of EDP167.

03

Conditions studied

  • Healthy Adult Male and Female Volunteers
  • Mild Dyslipidemia

Browse trials for

Keywords

  • Dyslipidemia
  • ANGPTL3
  • siRNA
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 18 to 60 years (inclusive) at the time of signing the form, male or female.
  2. Male subjects weighing ≥50.0 kg, female subjects weighing ≥45.0 kg, and (BMI) between 18.0 and 35.0 kg/m² (inclusive).
  3. Subjects with fasting serum TG ≥1.13 mmol/L and \<5.6 mmol/L, and LDL-C ≥1.8 mmol/L and \<4.9 mmol/L at screening.
  4. Subjects with no abnormalities or only minor abnormalities judged by the investigator as clinically insignificant (excluding lipid laboratory tests) upon physical examination, vital signs, 12-lead , posteroanterior and lateral chest X-rays, abdominal ultrasound, and laboratory tests at screening.
  5. Subjects who have maintained a stable dietary habit for at least 4 weeks before dose administration, and have no plans to significantly change their diet or body weight during the study.
  6. Female subjects of or male subjects with partners of childbearing potential must agree to use highly effective from signing the informed consent form until 6 months after dosing and refrain from donating sperm or eggs.
  7. Subjects who voluntarily sign the written informed consent form, understand the study procedures and content, are able to communicate well with the investigator, and are willing to comply with the relevant study regulations.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with known allergy/ to the drug, its components, or drugs of the same class.
  2. Subjects with a history or current presence of serious or diseases/abnormalities, including but not limited to cardiovascular, respiratory, endocrine, gastrointestinal, renal, hepatic, biliary, dermatologic, hematologic, immunologic, neurologic, or psychiatric diseases/abnormalities, , or any diseases (except for dyslipidemia) that the investigator considers to pose safety concerns or interfere with the pharmacokinetic evaluation.
  3. Subjects who have undergone major surgery within 3 months prior to screening, or have undergone surgery that may significantly affect drug absorption, distribution, metabolism, or excretion, or who plan to undergo elective surgery during the study.
  4. Subjects with any of the following laboratory abnormalities at screening: total (TBIL), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) >1.5×; (ALT) or aspartate aminotransferase (AST) >ULN.
  5. Subjects with any of the following 12-lead findings: >450 ms or any other clinically significant abnormal ECG result.
  6. Subjects with tattoos, scars, or birthmarks on the abdomen, upper arms, or thighs that may interfere with the assessment of injection site reactions.
  7. Subjects who have used any prescription drugs, over-the-counter (OTC) medications, Chinese herbal medicines, or health supplements within 14 days prior to dosing; or for whom administration occurs within 5 half-lives of any prior medication (based on the longer period); or who have used any medication known to affect lipid metabolism within 90 days prior to screening.
  8. Subjects who have received any within 4 weeks prior to screening, or who plan to receive any live vaccine during the study.
  9. Subjects who have used any antisense oligonucleotide (ASO) or small interfering RNA (siRNA) therapy within 12 months prior to screening.
  10. Subjects with a history of drug abuse/substance abuse, or a positive result for the specified drugs (ketamine, marijuana, morphine, MDMA, methamphetamine, cocaine) in the urine drug screen at screening.
  11. Subjects who regularly consumed alcohol within 3 months prior to screening (defined as >14 units of alcohol per week; 1 unit = 360 mL of beer, or 45 mL of spirits with 40% alcohol, or 150 mL of wine), or are unwilling to abstain from alcohol during the study, or have a breath alcohol test result >0 mg/100 mL.
  12. Subjects who consumed excessive amounts of tea, coffee, or caffeinated beverages (defined as >8 cups per day; 1 cup = 250 mL) within 3 months prior to screening, or consumed any such beverages within 48 hours prior to dosing, or are unwilling to abstain from them during the study.
  13. Current smokers, or subjects with a positive urine nicotine test at screening, or former smokers who have quit smoking for less than 6 months.
  14. Subjects with positive test results for surface antigen (HBsAg), virus antibody (HCVAb), (HIV) antibody, or specific treponemal antibody (for syphilis) at screening.
  15. Subjects with intolerance to venipuncture, difficulty in blood sampling, or a history of needle or blood syncope.
  16. Subjects who have donated blood or experienced significant blood loss (≥400 mL) within 3 months prior to screening.
  17. Subjects who have participated in, or are currently participating in, another clinical trial and have received the investigational product/device or placebo within 3 months prior to screening.
  18. Female subjects with a positive pregnancy test at screening, or who are breastfeeding, or who plan to become pregnant during the study period.
  19. Any other condition that the investigator deems inappropriate for the subject to participate in this clinical trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Group 1

    EDP167 35mg (N=6) and Placebo (N=2)

    Drug: EDP167 · Drug: Placebo

  • Experimental
    Group 2

    EDP167 100mg (N=6) and Placebo (N=2)

    Drug: EDP167 · Drug: Placebo

  • Experimental
    Group 3

    EDP167 200mg (N=6) and Placebo (N=2)

    Drug: EDP167 · Drug: Placebo

  • Experimental
    Group 4

    EDP167 300mg (N=6) and Placebo (N=2)

    Drug: EDP167 · Drug: Placebo

  • Experimental
    Group 5

    EDP167 400mg (N=6) and Placebo (N=2)

    Drug: EDP167 · Drug: Placebo

Interventions

  • DrugEDP167

    EDP167 sc injection

  • DrugPlacebo

    Sterile normal saline (0.9% NaCl) sc injection

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of a single subcutaneous injection of EDP167 in adult subjects.

    Number of participants with adverse events and serious adverse events, with clinically significant changes in vital signs, in electrocardiogram readings, in physical examination, and in laboratory tests.

    Time frame: Up to 85 days post-dose

Secondary outcomes

  1. To evaluate the plasma concentration-time area under curve (AUC) of a single subcutaneous injection of EDP167 in adult subjects.

    Concentration-time area under curve (AUC) of EDP167 in plasma

    Time frame: Up to 48 hours post-dose

  2. To evaluate the time to peak concentration (Tmax) of a single subcutaneous injection of EDP167 in adult subjects.

    Time to peak concentration (Tmax) of EDP167 in plasma

    Time frame: Up to 48 hours post-dose

  3. To evaluate the peak concentration (Cmax) of a single subcutaneous injection of EDP167 in adult subjects.

    Peak concentration (Cmax) of EDP167 in plasma

    Time frame: Up to 48 hours post-dose

  4. To evaluate the apparent volume of distribution (Vd) of a single subcutaneous injection of EDP167 in adult subjects.

    Time frame: Up to 48 hours post-dose

  5. To evaluate the clearance (CL) of a single subcutaneous injection of EDP167 in adult subjects.

    Time frame: Up to 48 hours post-dose

  6. To evaluate the elimination half-time (t1/2) of a single subcutaneous injection of EDP167 in adult subjects.

    Time frame: Up to 48 hours post-dose

  7. To evaluate the pharmacodynamic characteristics (ANGPTL3) of a single subcutaneous injection of EDP167 in adult subjects.

    Change from baseline in fasting serum ANGPTL3 level.

    Time frame: Up to 85 days post-dose

  8. To evaluate the pharmacodynamic characteristics (TG) of a single subcutaneous injection of EDP167 in adult subjects.

    Change from baseline in fasting serum TG level.

    Time frame: Up to 85 days post-dose

  9. To evaluate the pharmacodynamic characteristics (LDL-C) of a single subcutaneous injection of EDP167 in adult subjects.

    Change from baseline in fasting serum LDL-C level.

    Time frame: Up to 85 days post-dose

  10. To evaluate the pharmacodynamic characteristics (TC) of a single subcutaneous injection of EDP167 in adult subjects.

    Change from baseline in fasting serum TC level.

    Time frame: Up to 85 days post-dose

  11. To evaluate the pharmacodynamic characteristics (non-HDL-C) of a single subcutaneous injection of EDP167 in adult subjects.

    Change from baseline in fasting serum non-HDL-C level.

    Time frame: Up to 85 days post-dose

  12. To evaluate the pharmacodynamic characteristics (VLDL-C) of a single subcutaneous injection of EDP167 in adult subjects.

    Change from baseline in fasting serum VLDL-C level.

    Time frame: Up to 85 days post-dose

  13. To evaluate the pharmacodynamic characteristics (HDL-C) of a single subcutaneous injection of EDP167 in adult subjects.

    Change from baseline in fasting serum HDL-C level.

    Time frame: Up to 85 days post-dose

  14. To evaluate the pharmacodynamic characteristics (Lp(a)) of a single subcutaneous injection of EDP167 in adult subjects.

    Change from baseline in fasting serum Lp(a) level.

    Time frame: Up to 85 days post-dose

  15. To evaluate the pharmacodynamic characteristics (ApoB) of a single subcutaneous injection of EDP167 in adult subjects.

    Change from baseline in fasting serum ApoB level.

    Time frame: Up to 85 days post-dose

  16. To evaluate the pharmacodynamic characteristics (ApoA-I) of a single subcutaneous injection of EDP167 in adult subjects.

    Change from baseline in fasting serum ApoA-I level.

    Time frame: Up to 85 days post-dose

  17. The effect of EDP167 injection on QT interval evaluated by C-QT analysis.

    The difference from baseline of QTcF after administration.

    Time frame: Up to 48 hours post-dose

  18. The effect of EDP167 injection on QT interval evaluated by C-QT analysis.

    The correlation between drug serum concentration and QTcF.

    Time frame: Up to 48 hours post-dose

  19. To evaluate the immunogenicity of EDP167.

    The incidence and titer of antibodies against EDP167.

    Time frame: Up to 85 days post-dose

07

Study locations

2 sites
  • Guangdong Provincial People's Hospital
    Guangzhou, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 5 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 17, 2026
StartActual
Jul 1, 2025
Primary completionActual
Dec 12, 2025
CompletionActual
Dec 12, 2025
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07412080
Lead sponsor
Eddingpharm (Zhuhai) Co., Ltd.
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Jul 1, 2025
Primary completion
Dec 12, 2025
Completion
Dec 12, 2025
Last update
Feb 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP167

Start the discussion